In vitro: Neratinib (0.001, 0.1 or 10 µM) was screened against a panel of 65 receptor targets including neurotransmitters, ion channels, prostaglandins, growth factors, steroids, second messengers, peptides, and various enzymes. Results were reported as percent inhibition of specific binding.